Dr. Glenn F. Pierce, M.D., Ph.D., is an Independent Consultant & Entrepreneur-In-Residence of Third Rock Ventures, LLC. He joined Third Rock Ventures in 2016. As an entrepreneur-in-residence, he focuses on research, development and translation in hemtatology across the portfolio. He served as a Senior Vice President of Hematology, Cell and Gene Therapies at Biogen Idec Inc. Dr. Pierce served as Senior Vice President of Hematology, Cell and Gene Therapies of Biogen Idec Hemophilia Therapeutic Area. Dr. Pierce retired from Biogen in 2014, where he served in various roles, including as head of global medical affairs and led the Hematology, Cell and Gene Therapies division and Senior Vice President of Global Medical Affairs. He served as the Senior Vice President and Chief Medical Officer (since 2009) of Biogen Idec Inc. He served as the Chief Medical Officer and Senior Vice President of Biogen Idec Hemophilia Therapeutic Area. Dr. Pierce joined Avigen, Inc. in November 2002 and served as Vice President of Research & Clinical Development. Dr. Pierce joined Biogen Idec's hemophilia therapeutic area in 2009. Before joining Avigen, Inc. Dr. Pierce served as Vice President of Therapeutic Product Development at Selective Genetics since 1998, which focuses on tissue regeneration. From 1994 to 1998, he served as Vice President, Preclinical Development at Prizm Pharmaceuticals. Prior to that, Dr. Pierce held a number of positions at Amgen Inc., and was instrumental in the development of Amgen's neurobiology program. He has more than 20 years of experience in biotechnology research and development, from the bench to the bedside in small, large, public and private biotech/biopharma firms, including Avigen, Selective Genetics, Inspiration and Amgen. He was Scientific Head of US Research Center and Vice President of Applied Research Hematology at Bayer Schering Pharma and Bayer Healthcare. He has served three terms as the President of the National Hemophilia Foundation (NHF) in 1992, 1993 and in 2002. He founded NHF's annual gene therapy workshop in 1996. Dr. Pierce has been a Director of Global Blood Therapeutics Inc. since February 8, 2016. He has been an Independent Director of Voyager Therapeutics, Inc. since January 05, 2017. He serves as a Director of BayBio and World Federation of Hemophilia. Dr. Pierce served on the Medical and Scientific Advisory Council at the Food and Drug Administration. He served as a Director of Bay Area Bioscience Association. Dr. Pierce holds numerous patents in various areas of drug delivery, tissue engineering, medical devices and viral vectors. He has published more than 100 papers in scientific and medical journals in related areas. He is a Co-author of over 150 scientific papers, has over 15 U.S. patents and is a member of numerous medical and scientific groups including the World Federation of Hemophilia (WFH), National Hemophilia Foundation (NHF), ISTH and ASH. He has more than 30 years of research and development experience working with biotechnology companies. He earned both his M.D. and a Ph.D. in Immunology and Experimental Pathology at Case Western Reserve University, prior to doing a residency and fellowship at Washington University in St. Louis. Dr. Pierce did postgraduate training in pathology and hematology research at Washington University. Dr. Glenn F. Pierce, M.D., Ph.D., is an Independent Consultant & Entrepreneur-In-Residence of Third Rock Ventures, LLC. He joined Third Rock Ventures in 2016. As an entrepreneur-in-residence, he focuses on research, development and translation in hemtatology across the portfolio. He served as a Senior Vice President of Hematology, Cell and Gene Therapies at Biogen Idec Inc. Dr. Pierce served as Senior Vice President of Hematology, Cell and Gene Therapies of Biogen Idec Hemophilia Therapeutic Area. Dr. Pierce retired from Biogen in 2014, where he served in various roles, including as head of global medical affairs and led the Hematology, Cell and Gene Therapies division and Senior Vice President of Global Medical Affairs. He served as the Senior Vice President and Chief Medical Officer (since 2009) of Biogen Idec Inc. He served as the Chief Medical Officer and Senior Vice President of Biogen Idec Hemophilia Therapeutic Area. Dr. Pierce joined Avigen, Inc. in November 2002 and served as Vice President of Research & Clinical Development. Dr. Pierce joined Biogen Idec's hemophilia therapeutic area in 2009. Before joining Avigen, Inc. Dr. Pierce served as Vice President of Therapeutic Product Development at Selective Genetics since 1998, which focuses on tissue regeneration. From 1994 to 1998, he served as Vice President, Preclinical Development at Prizm Pharmaceuticals. Prior to that, Dr. Pierce held a number of positions at Amgen Inc., and was instrumental in the development of Amgen's neurobiology program. He has more than 20 years of experience in biotechnology research and development, from the bench to the bedside in small, large, public and private biotech/biopharma firms, including Avigen, Selective Genetics, Inspiration and Amgen. He was Scientific Head of US Research Center and Vice President of Applied Research Hematology at Bayer Schering Pharma and Bayer Healthcare. He has served three terms as the President of the National Hemophilia Foundation (NHF) in 1992, 1993 and in 2002. He founded NHF's annual gene therapy workshop in 1996. Dr. Pierce has been a Director of Global Blood Therapeutics Inc. since February 8, 2016. He has been an Independent Director of Voyager Therapeutics, Inc. since January 05, 2017. He serves as a Director of BayBio and World Federation of Hemophilia. Dr. Pierce served on the Medical and Scientific Advisory Council at the Food and Drug Administration. He served as a Director of Bay Area Bioscience Association. Dr. Pierce holds numerous patents in various areas of drug delivery, tissue engineering, medical devices and viral vectors. He has published more than 100 papers in scientific and medical journals in related areas. He is a Co-author of over 150 scientific papers, has over 15 U.S. patents and is a member of numerous medical and scientific groups including the World Federation of Hemophilia (WFH), National Hemophilia Foundation (NHF), ISTH and ASH. He has more than 30 years of research and development experience working with biotechnology companies. He earned both his M.D. and a Ph.D. in Immunology and Experimental Pathology at Case Western Reserve University, prior to doing a residency and fellowship at Washington University in St. Louis. Dr. Pierce did postgraduate training in pathology and hematology research at Washington University.

Blood Research & Hematologic Diseases